Commercial Antithrombin Concentrate Contains Inactive L-forms of Antithrombin

Summary

The preparation of antithrombin concentrate for clinical use requires a viral inactivation step. In most commercial preparations this is achieved by heat pasteurisation. This process would be expected to alter the conformation of antithrombin from the active native species to an inactive latent (L-form) state (1, 2). To determine if this occurs during commercial preparation and to identify the proportion of the product in the inactive state, we examined the various antithrombin conformations within a therapeutic concentrate. The antithrombin concentrate was separated into five fractions by heparin-Sepharose chromatography. The fraction with the highest heparin affinity retained full activity, whereas the four fractions with reduced heparin affinity (~40% of the total antithrombin) had lost their inhibitory function. These inactive antithrombins were intact, monomeric, thermostable and resistant to unfolding in 8 M urea. Moreover, the protein patterns on isoelectric focusing and non-denaturing-PAGE showed that there were at least two different L-forms with isoelectric points separate from the native active species. Our findings demonstrate that approximately 40% of the antithrombin preparation examined exists as inactive l-forms. The clinical significance of administering this altered material is uncertain.

• References

• 1 Chang WSW, Bruce D, Lomas DA, Carrell RW, Wardell MR. Antithrombin, pasteurisation and latency:probing the reactive centre loop conformation. Br J Haematol 1994; 86 (Suppl. 01) 42
• 2 Chang WSW. Conformational mobility and interactions of the serpins. PhD thesis Cambridge University; UK: 1995. pp 92-132
• 3 Murano G, Williams L, Miller-Andersson M, Aronson DL, King C. Some properties of antithrombin III and its concentration in human plasma. Thromb Res 1980; 18: 259-262
• 4 Carrell RW, Owen MC. Plakalbumin, α₁-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis. Nature 1985; 317: 730-732
• 5 Carrell RW, Travis J. α₁Antitrypsin and the serpins:variation and countervariation. Trends Biochem Sci 1985; 10: 20-24
• 6 Danielsson Å, Bjoӧrk I. Antithrombin and related inhibitors of coagulation proteinases. In: Proteinase Inhibitors. Barrett AJ, Salvesen G. eds. Elsevier Science Publishers; Amsterdam, NL: 1986. pp 489-513
• 7 Thaler E, Lechnerk P. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-390
• 8 Winter JH, Fenech A, Ridley W. Familial antithrombin III deficiency. QJ Med 1982; 51: 29-33
• 9 Bick RL, Bick MD, Fekete LF. Antithrombin III patterns in disseminated intravascular coagulation. Am J Clin Path 1980; 73: 577-583
• 10 Wilson RF, Mammen EF, Robson MC. Antithrombin, prekallikrein, and fibronectin levels in surgical patients. Arch Surg 1986; 121: 635-640
• 11 Blauhut B, Necek S, Vinazzer H, Bergman H. Substitution therapy with antithrombin III concentrate in shock and DIC. Thromb Res 1982; 27: 271-278
• 12 Schechter I, Berger A. On the size of the active site in proteases 1 papain. Biochem Biophys Res Commun 1967; 27: 157-262
• 13 Stein PE, Leslie AGW, Finch JT, Tumell WG, McLaughlin PJ, Carrell RW. Crystal structure of ovalbumin as a model for the reactive centre of serpins. Nature 1990; 347: 99-102
• 14 Lӧebermann H, Tokuoka R, Deisenhofer J, Huber R. Human α₁-proteinase inhibitor:crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984; 177: 531-556
• 15 Mourey L, Samama J, Delarue M, Petitou M, Choay J, Moras D. Crystal structure of cleaved bovine antithrombin III at 3.2 υ resolution. J Mol Biol 1993; 232: 223-241
• 16 Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3 υ structure of dimeric antithrombin. Structure 1994; 02: 257-270
• 17 Schreuder HA, de BoerB, Dijkema R, Mulders J, Theunissen HJM, Grootenhuis PDJ, Hoi WGJ. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions. Nature Struct Biol 1994; 01: 48-54
• 18 Smith JK, Winkelman L, Evans DR, Haddon ME, Sims GA. A pasteurised antithrombin III concentrate for clinical use. Vox Sang 1985; 48: 325-332
• 19 Lomas DA, Elliott PR, Chang WSW, Wardell MR, Carrell RW. Preparation and characterization of latent α₁-antitrypsin. J Biol Chem 1995; 270: 5282-5288
• 20 McKay EJ. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981; 21: 375-382
• 21 Nordenman B, Nystrӧm C, Bjӧrk I. The size and shape of human and bovine antithrombin III. Eur J Biochem 1977; 78: 195-203
• 22 Olson ST, Bjӧrk I, Shore JD. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood coagulation proteinases by antithrombin. Methods Enzymol 1993; 222: 525-559
• 23 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
• 24 Goldenberg DP. Analysis of protein conformation by gel electrophoresis. In: Protein Structure, a Practical Approach. Creighton TE. ed. IRL Press; Oxford, UK: 1989. pp 225-250
• 25 Mast AE, Enghild JJ, Pizzo SV, Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase complexed and reactive site cleaved serpins:comparison of α₁-proteinase inhibitor, a j-antichymotrypsin, antithrombin III, α₂-antiplasmin, angioten-sinogen and ovalbumin. Biochemistry 1991; 30: 1723-1730
• 26 Lomas DA, Evans DL, Stone SR, Chang WSW, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of α₁-antitrypsin. Biochemistry 1993; 32: 500-508
• 27 Chang WSW, Wardell MR, Lomas DA, Carrell RW. Probing Serpin reactive loop conformations by proteolytic cleavage. Biochem J 1996; 314: 647-653
• 28 Hoffman DL. Purification and large scale preparation of antithrombin III. Am J Med 1989; 87: 23S-26S
• 29 Winkelman L, Haddon ME. Pasteurisation Induced Changes in antithrombin III Concentrate. Thromb Res 1986; 43: 219-227
• 30 Mottonen J, Strand A, Symersky J, Sweet RM, Danley DE, Geoghegan KF, Gerard RD, Goldsmith EJ. Structural basis of latency in plasminogen activator inhibitor-1. Nature 1992; 355: 270-273
• 31 Lomas DA, Stone SR, Llewellyn-Jones C, Keogan MT, Wang Z, Rubin H, Carrell RW, Stockley RA. The control of neutrophil chemotaxis by inhibitors of Cathepsin G and Chymotrypsin. J Biol Chem 1995; 270: 23437-23443